The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
The impact of major depressive disorder on the short‐ and long‐term outcome of Crohn's disease treatment with infliximab
Open accessAbstract
Summary: Background: Major depressive disorder is the most common psychiatric diagnosis in Crohn's disease. In other chronic diseases, evidence suggests that depression influences the course of the disease. Strong evidence of such a mediating role of major depressive disorder in Crohn's disease has never been found. Aim: To assess the relationship between major depressive disorder and outcome of treatment of luminal Crohn's disease with infliximab. Methods: In this prospective study, 100 consecutive unselected patients underwent assessment of psychosocial, demographical disease‐related biological and clinical parameters at baseline and at 4 weeks after infliximab. Major depressive disorder was diagnosed using the Patient Health Questionnaire. Subsequently, the patients were followed up clinically until the next flare or during 9 months. Results: The Crohn's disease responded in 75% of the patients, and remission was achieved in 60%. The presence of major depressive disorder at baseline predicted a lower remission rate (OR = 0.166, 95% CI = 0.049–0.567, P = 0.004). At follow‐up, 88% of the patients needed retreatment. At univariate regression analysis, major depressive disorder significantly decreased time to retreatment (P = 0.001). Multivariate Cox regression confirmed major depressive disorder as an independent determinant of active disease both at baseline and at re‐evaluation (hazard ratio = 2.271, 95% CI: 1.36–3.79, P = 0.002). Conclusion: Major depressive disorder is a risk factor for failure to achieve remission with infliximab and for earlier retreatment in patients with active luminal Crohn's disease. Assessment and management of major depressive disorder should be part of the clinical approach to patients with Crohn's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“whereas only 43% of patients in the placebo group experienced clinically significant improvements in fatigue at Week 12, 58% of those in the etanercept group experienced such improvements”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Persoons et al., 2005
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
DiMatteo, M. R., Lepper, H. S., & Croghan, T. W. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.14.2101 · Cited by 4,177
Depression and Pain Comorbidity: A Literature Review
Bair, M. J., Robinson, R. L., Katon, W., & Kroenke, K. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.20.2433 · Cited by 3,463
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Self-citationInfliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,748
Self-citationThe twenty-item Toronto Alexithymia scale—II. Convergent, discriminant, and concurrent validity
Bagby, R. M., Taylor, G. J., & Parker, J. D. A. (1994) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(94)90006-x · Cited by 2,431
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,222
Self-citationThe Relationship of Depression to Cardiovascular Disease: Epidemiology, Biology, and Treatment
Musselman, D. L., Evans, D. L., & Nemeroff, C. B. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.7.580 · Cited by 1,532
Gasché, C., Schölmerich, J., Brynskov, J., D’Haens, G., Hanauer, S. B., Irvine, J. E., Jewell, D. P., Rachmilewitz, D., Sachar, D. B., Sandborn, W. J., et al. (2000) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200002000-00002 · Cited by 1,135
Research works printed but not linked: 13
- 10.1016/S0006-3223(03)00273-7 · DOI
- 10.1016/S0006-3223(03)00323-8 · DOI
- 10.1016/0016-5085(90)91234-W · DOI
- 10.1159/000288617 · DOI
- Levenstein S, 1994, Psychological stress and disease activity in ulcerative colitis: a multidimensional cross‐sectional study [see comments], Am J Gastroenterol, 89, 1219
- Lashner BA, 2000, Inflammatory Bowel Disease, 305
- 10.1056/NEJMra020831 · DOI
- 10.1046/j.1445-5994.2001.00039.x · DOI
- 10.1002/ibd.3780060103 · DOI
- 10.1016/S0016-5085(08)80560-4 · DOI
- Association AP, 1994, Diagnostic and Statistical Manual of Mental Disorders
- 10.1159/000288990 · DOI
- Sonderen E, 1993, Sociale Steun Lijst‐Interacties (SSL‐I) en Sociale Steun Lijst‐Discrepanties (SSL‐D). Een handleiding
Cited by
Sorted by citations
Items 201–214 of 214
Vastrad, B. M., Pattanashetti, S., & Vastrad, C. M. (2025) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2025.100119 · Cited by 3
Taylor, A. L., Kogan, J. N., Meyers, J., Lupe, S. E., Click, B. H., Cohen, B., Szigethy, E., Keefer, L., & Nikolajski, C. (2023) · Journal of Clinical Psychology in Medical Settings · doi:10.1007/s10880-023-09979-9
“…counterparts, further compounding disease complexity and negatively impacting medical/surgical treatment response, adherence to treatment regimens, and disease-related quality of life and functioning (Barberio et al., 2021; Mikocka-Walus et al., 2016; Persoons et al., 2005; Regueiro et al., 2017).”
Hmar, E. B. L., Paul, S., Boruah, N., Sarkar, P., Borah, S., & Sharma, H. K. (2021) · Current Pathobiology Reports · doi:10.1007/s40139-020-00218-6 · Cited by 4
Brain-gut axis: From the conditioned reflex to the microbiota-gut-brain communication system
Gyires, K. (2020) · Integrative Physiology · doi:10.33910/2687-1270-2020-1-4-266-276
“Therefore, identification and management of major depressive disorders should be part of the clinical treatment (Persoons et al. 2005).”
BackgroundChoi, G., Han, K., Chun, J., Im, J., & Kim, J. S. (2018) · doi:10.1016/s0016-5085(18)32205-4
“19 have shown that anxiety and depression may be a risk factor for the development of IBD (28-30).”
BackgroundHypothesis of neuroinflammation in depression
Dolfi, A., & Talasman, A.-A. (2017) · Romanian Journal of Psychiatry & Psychotherapy · doi:10.37897/rjpp.2017.4.5
Dai, C., Jiang, M., & Sun, M.-J. (2016) · Journal of Crohn's & Colitis · doi:10.1093/ecco-jcc/jjw215
Prevalence of mental health disorders in inflammatory bowel disease: an Australian outpatient cohort
Knowles, S. R., Tribbick, D., Salzberg, M. R., Ftanou, M., Connell, W. R., Macrae, F., Kamm, M. A., Bates, G. W., Cunningham, G., & Austin, D. (2015) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s77567 · Cited by 39
“Research also indicates that ongoing psychological distress can exacerbate disease activity, and increase the risk of flare-ups and health care costs.(4,6,7) Given this, several experts have called for mental health screening and targeted treatment of psychological conditions in IBD cohorts.”
Maunder, R. (2011) · doi:10.1002/9781444342574.ch47
Lee, T. W. T. (2011) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3w04f
Does hypnotherapy have a role in managing inflammatory bowel disease?
Wahed, M., & Emmanuel, A. V. (2010) · Gastrointestinal Nursing · doi:10.12968/gasn.2010.8.4.48077
Boye, B., Jahnsen, J., Lundin, K. E. A., Wilhelmsen, I., Malt, U. F., & Jantschek, G. (2007) · Psychosomatik und Konsiliarpsychiatrie · doi:10.1007/s11800-007-0026-8
Translational Medicine Strategies in Drug Development for Mood Disorders
Pan, Z., Grovu, R. C., & McIntyre, R. S. (2019) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-803161-2.00023-0 · Cited by 2
Barriers to Successful Outcomes in Patients with Inflammatory Bowel Diseases
Ligler, R., & Horst, S. (2015) · Springer eBooks · doi:10.1007/978-3-319-22285-1_1
Metadata
- Authors
- PERSOONS, P., VERMEIRE, S., DEMYTTENAERE, K., FISCHLER, B., VANDENBERGHE, J., VAN OUDENHOVE, L., PIERIK, M., HLAVATY, T., VAN ASSCHE, G., NOMAN, M., & RUTGEERTS, P.
- Affiliations
- KU Leuven (BE)
- Corresponding author
- RUTGEERTS, P.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2005-07
- Volume
- 22
- Issue
- 2
- Pages
- 101-110
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2025629977
- Cited by
- 253
- References
- 0
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 12 · 2023: 12 · 2022: 17 · 2021: 13 · 2020: 9 · 2019: 16 · 2018: 19 · 2017: 18 · 2016: 19 · 2015: 15 · 2014: 18 · 2013: 13 · 2012: 9
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- green
- lirias.kuleuven.be
- Licence
- Locations
- Alimentary Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Lirias (submittedVersion, other-oa)
- Funders
- Vlaamse regering
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- major depressive disorder, Crohn's disease, infliximab, treatment response, remission, retreatment, disease flares, psychiatric comorbidity, luminal Crohn's disease, biologic therapy
- MeSH terms
- Infliximab, Adult, Affective Symptoms, Antibodies, Monoclonal, Anxiety, Crohn Disease, Depressive Disorder, Major, Major Depressive Disorder, Female, Gastrointestinal Agents, Humans, Male, Prospective Studies, Regression Analysis, Risk Factors, Sleep Wake Disorders, Social Support, Multivariate Analysis, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
